Avantor
AVTR
Market cap $9.17B

13.07 USD

-0.47

3.47%

At close Jun 13, 4:00 PM EDT

After hours

13.55

+0.48

3.67%

1 day

-3.47%

5 days

-1.80%

1 month

-1.73%

3 months

-17.38%

6 months

-41.47%

Year to date

-38.35%

1 year

-40.64%

5 years

-24.14%

10 years

-9.86%

About: Avantor Inc provider of products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company has three geographic segments: the Americas, Europe, and AMEA. The company's product group consists of Equipment & instrumentation, Services & specialty procurement, Proprietary materials & consumables, and Third-party materials & consumables. Materials & consumables include high-purity chemicals and reagents, lab products and supplies, specialized formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, and education and microbiology and clinical trial kits, peristaltic pumps and fluid handling tips.

Employees: 13,500

Healthcare Medical Instruments & Supplies

0

Funds holding %

of 7,296 funds

0

Analysts bullish %

of 7 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

127% more call options, than puts

Call options by funds: $35.7M | Put options by funds: $15.7M

16% more repeat investments, than reductions

Existing positions increased: 191 | Existing positions reduced: 164

0.37% less ownership

Funds ownership: 100.63% [Q4 2024] → 100.25% (-0.37%) [Q1 2025]

3% less first-time investments, than exits

New positions opened: 64 | Existing positions closed: 66

2% less funds holding

Funds holding: 481 [Q4 2024] → 471 (-10) [Q1 2025]

23% less capital invested

Capital invested by funds: $14.4B [Q4 2024] → $11.1B (-$3.3B) [Q1 2025]

36% less funds holding in top 10

Funds holding in top 10: 11 [Q4 2024] → 7 (-4) [Q1 2025]

See Fund Rankings

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$14

7%

upside

Avg. target

$16.71

28%

upside

High target

$22

68%

upside

7 analyst ratings

4 positive

57%

3 neutral

43%

0 negative

0%

Goldman Sachs Matthew Sykes	7%upside $14	Neutral Downgraded	29 Apr 2025
RBC Capital Conor McNamara	53%upside $20	Outperform Maintained	28 Apr 2025
Stifel Daniel Arias	7%upside $14	Hold Downgraded	28 Apr 2025
Barclays Luke Sergott	15%upside $15	Overweight Maintained	28 Apr 2025
Morgan Stanley Tejas Savant	15%upside $15	Equal-Weight Downgraded	28 Apr 2025

See Analyst Rankings

Financial journalist opinion

Avantor® to Participate in the 2025 RBC Capital Markets Global Healthcare Conference

RADNOR, Pa. , May 16, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that Brent Jones, Executive Vice President and Chief Financial Officer, will be participating in a fireside chat at the RBC Capital Markets Global Healthcare Conference in New York on Tuesday, May 20, 2025 at approximately 8:00 a.m.

Avantor® to Participate in the 2025 RBC Capital Markets Global Healthcare Conference

Avantor® to Participate in Bank of America Securities 2025 Health Care Conference

RADNOR, Pa. , May 2, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that Michael Stubblefield, President and CEO, will be participating in a fireside chat at the Bank of America Securities 2025 Health Care Conference in Las Vegas on Tuesday, May 13, 2025 at approximately 10:00 a.m.

Avantor® to Participate in Bank of America Securities 2025 Health Care Conference

Zacks Investment Research

Avantor Stock Declines Despite Q1 Earnings In-Line, Revenues Down Y/Y

AVTR's Bioscience Production segment witnesses robust growth amid macroeconomic pressures.

Avantor Stock Declines Despite Q1 Earnings In-Line, Revenues Down Y/Y

Avantor Analysts Cut Their Forecasts After Q1 Results

Avantor Inc AVTR reported in-line earnings for its first quarter on Friday.

Avantor Analysts Cut Their Forecasts After Q1 Results

Avantor: A Healthier Diagnosis As Expectations Cool

Avantor's shares have nearly halved since October, driven by lackluster organic growth, elevated debt, and a mixed financial track record. The company operates in two segments, generating nearly $7 billion in sales, with significant exposure to laboratory solutions and bioscience production. Despite a reduction in net debt and lower earnings multiples, the business faces ongoing challenges, including flat organic growth and a high leverage ratio.

Avantor: A Healthier Diagnosis As Expectations Cool

Avantor Sees Steady Earnings, Plans Leadership Change And Strategy Shift

Avantor Inc AVTR on Friday reported adjusted EPS of 23 cents in line with consensus.

Avantor Sees Steady Earnings, Plans Leadership Change And Strategy Shift

Avantor Stock Plummets as Firm's CEO Set to Leave Amid Sales Slump, Outlook Cut

Avantor (AVTR) shares sank 16% Friday after the maker of lab chemicals and other life sciences products announced its CEO was resigning, reported weaker-than-expected net sales as government spending fell, and slashed its guidance.

Avantor Stock Plummets as Firm's CEO Set to Leave Amid Sales Slump, Outlook Cut

Avantor, Inc. (AVTR) Q1 2025 Earnings Call Transcript

Avantor, Inc. (NYSE:AVTR ) Q1 2025 Earnings Call April 25, 2025 8:00 AM ET Company Participants Allison Hosak - SVP of Global Communications and Brand Michael Stubblefield - President and CEO R. Brent Jones - EVP and CFO Conference Call Participants Michael Ryskin - Bank of America Securities Vijay Kumar - Evercore ISI Rachel Vatnsdal - J.P.

Avantor, Inc. (AVTR) Q1 2025 Earnings Call Transcript

Zacks Investment Research

Compared to Estimates, Avantor (AVTR) Q1 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Avantor (AVTR) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Compared to Estimates, Avantor (AVTR) Q1 Earnings: A Look at Key Metrics

Zacks Investment Research

Avantor, Inc. (AVTR) Q1 Earnings Meet Estimates

Avantor, Inc. (AVTR) came out with quarterly earnings of $0.23 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.22 per share a year ago.

Avantor, Inc. (AVTR) Q1 Earnings Meet Estimates

See News Rankings

Charts implemented using Lightweight Charts™